{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:44:07Z","timestamp":1789764247549,"version":"4.0.1"},"reference-count":204,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1038\/s41582-022-00751-5","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T16:10:38Z","timestamp":1670515838000},"page":"39-52","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Prospects for gene replacement therapies in amyotrophic lateral sclerosis"],"prefix":"10.1038","volume":"19","author":[{"given":"Ilaria","family":"Giovannelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Higginbottom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7468-5917","authenticated-orcid":false,"given":"Janine","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimoun","family":"Azzouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8925-2567","authenticated-orcid":false,"given":"Pamela J.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"key":"751_CR1","doi-asserted-by":"publisher","first-page":"17071","DOI":"10.1038\/nrdp.2017.71","volume":"3","author":"O Hardiman","year":"2017","unstructured":"Hardiman, O. et al. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Prim. 3, 17071 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"751_CR2","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1242\/dmm.029058","volume":"10","author":"P Van Damme","year":"2017","unstructured":"Van Damme, P., Robberecht, W. & Van Den Bosch, L. Modelling amyotrophic lateral sclerosis: progress and possibilities. Dis. Model. Mech. 10, 537\u2013549 (2017).","journal-title":"Dis. Model. Mech."},{"key":"751_CR3","doi-asserted-by":"publisher","first-page":"7775","DOI":"10.3390\/molecules20057775","volume":"20","author":"N Nagoshi","year":"2015","unstructured":"Nagoshi, N., Nakashima, H. & Fehlings, M. G. Riluzole as a neuroprotective drug for spinal cord injury: from bench to bedside. Molecules 20, 7775\u20137789 (2015).","journal-title":"Molecules"},{"key":"751_CR4","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1474-4422(18)30054-1","volume":"17","author":"T Fang","year":"2018","unstructured":"Fang, T. et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 17, 416\u2013422 (2018).","journal-title":"Lancet Neurol."},{"key":"751_CR5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","volume":"16","author":"Edaravone (MCI-186) ALS 19 Study Group.","year":"2017","unstructured":"Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 16, 505\u2013512 (2017).","journal-title":"Lancet Neurol."},{"key":"751_CR6","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.expneurol.2015.09.019","volume":"275","author":"AE King","year":"2016","unstructured":"King, A. E., Woodhouse, A., Kirkcaldie, M. T. & Vickers, J. C. Excitotoxicity in ALS: overstimulation, or overreaction? Exp. Neurol. 275, 162\u2013171 (2016).","journal-title":"Exp. Neurol."},{"key":"751_CR7","doi-asserted-by":"publisher","first-page":"783624","DOI":"10.3389\/fnins.2021.783624","volume":"15","author":"BC Benson","year":"2021","unstructured":"Benson, B. C., Shaw, P. J., Azzouz, M., Highley, J. R. & Hautbergue, G. M. Proteinopathies as hallmarks of impaired gene expression, proteostasis and mitochondrial function in amyotrophic lateral sclerosis. Front. Neurosci. 15, 783624 (2021).","journal-title":"Front. Neurosci."},{"key":"751_CR8","doi-asserted-by":"publisher","first-page":"132933","DOI":"10.1016\/j.neulet.2017.06.052","volume":"710","author":"EF Smith","year":"2019","unstructured":"Smith, E. F., Shaw, P. J. & De Vos, K. J. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci. Lett. 710, 132933 (2019).","journal-title":"Neurosci. Lett."},{"key":"751_CR9","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.freeradbiomed.2009.11.018","volume":"48","author":"SC Barber","year":"2010","unstructured":"Barber, S. C. & Shaw, P. J. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free. Radic. Biol. Med. 48, 629\u2013641 (2010).","journal-title":"Free. Radic. Biol. Med."},{"key":"751_CR10","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3389\/fimmu.2017.01005","volume":"8","author":"J Liu","year":"2017","unstructured":"Liu, J. & Wang, F. Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications. Front. Immunol. 8, 1005 (2017).","journal-title":"Front. Immunol."},{"key":"751_CR11","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3389\/fgene.2018.00712","volume":"9","author":"Z Butti","year":"2018","unstructured":"Butti, Z. & Patten, S. A. RNA dysregulation in amyotrophic lateral sclerosis. Front. Genet. 9, 712 (2018).","journal-title":"Front. Genet."},{"key":"751_CR12","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1474-4422(16)30199-5","volume":"15","author":"A Al-Chalabi","year":"2016","unstructured":"Al-Chalabi, A. et al. Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol. 15, 1182\u20131194 (2016).","journal-title":"Lancet Neurol."},{"key":"751_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nrneurol.2011.150","volume":"7","author":"PM Andersen","year":"2011","unstructured":"Andersen, P. M. & Al-Chalabi, A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat. Rev. Neurol. 7, 603\u2013615 (2011).","journal-title":"Nat. Rev. Neurol."},{"key":"751_CR14","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3389\/fnins.2019.01310","volume":"13","author":"R Mejzini","year":"2019","unstructured":"Mejzini, R. et al. ALS genetics, mechanisms, and therapeutics: where are we now? Front. Neurosci. 13, 1310 (2019).","journal-title":"Front. Neurosci."},{"key":"751_CR15","doi-asserted-by":"publisher","first-page":"684","DOI":"10.3389\/fnins.2020.00684","volume":"14","author":"R Ranganathan","year":"2020","unstructured":"Ranganathan, R. et al. Multifaceted genes in amyotrophic lateral sclerosis-frontotemporal dementia. Front. Neurosci. 14, 684 (2020).","journal-title":"Front. Neurosci."},{"key":"751_CR16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nrneurol.2014.78","volume":"10","author":"H Deng","year":"2014","unstructured":"Deng, H., Gao, K. & Jankovic, J. The role of FUS gene variants in neurodegenerative diseases. Nat. Rev. Neurol. 10, 337\u2013348 (2014).","journal-title":"Nat. Rev. Neurol."},{"key":"751_CR17","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell, J. R. et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N. Engl. J. Med. 377, 1713\u20131722 (2017).","journal-title":"N. Engl. J. Med."},{"key":"751_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ppul.24203","volume":"54","author":"S Al-Zaidy","year":"2019","unstructured":"Al-Zaidy, S. et al. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr. Pulmonol. 54, 179\u2013185 (2019).","journal-title":"Pediatr. Pulmonol."},{"key":"751_CR19","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","volume":"79","author":"SM Hoy","year":"2019","unstructured":"Hoy, S. M. Onasemnogene abeparvovec: first global approval. Drugs 79, 1255\u20131262 (2019).","journal-title":"Drugs"},{"key":"751_CR20","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMra1706910","volume":"381","author":"KA High","year":"2019","unstructured":"High, K. A. & Roncarolo, M. G. Gene therapy. N. Engl. J. Med. 381, 455\u2013464 (2019).","journal-title":"N. Engl. J. Med."},{"key":"751_CR21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11010-020-03834-3","volume":"474","author":"R Tang","year":"2020","unstructured":"Tang, R. & Xu, Z. Gene therapy: a double-edged sword with great powers. Mol. Cell Biochem. 474, 73\u201381 (2020).","journal-title":"Mol. Cell Biochem."},{"key":"751_CR22","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1016\/j.ymthe.2021.04.008","volume":"29","author":"DA Amado","year":"2021","unstructured":"Amado, D. A. & Davidson, B. L. Gene therapy for ALS: a review. Mol. Ther. 29, 3345\u20133358 (2021).","journal-title":"Mol. Ther."},{"key":"751_CR23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","volume":"15","author":"D Adams","year":"2019","unstructured":"Adams, D., Koike, H., Slama, M. & Coelho, T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat. Rev. Neurol. 15, 387\u2013404 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"751_CR24","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","volume":"78","author":"SJ Keam","year":"2018","unstructured":"Keam, S. J. Inotersen: first global approval. Drugs 78, 1371\u20131376 (2018).","journal-title":"Drugs"},{"key":"751_CR25","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41582-020-00413-4","volume":"16","author":"E Mercuri","year":"2020","unstructured":"Mercuri, E., Pera, M. C., Scoto, M., Finkel, R. & Muntoni, F. Spinal muscular atrophy \u2013 insights and challenges in the treatment era. Nat. Rev. Neurol. 16, 706\u2013715 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"751_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3349\/ymj.2020.61.4.273","volume":"61","author":"Q Li","year":"2020","unstructured":"Li, Q. Nusinersen as a therapeutic agent for spinal muscular atrophy. Yonsei Med. J. 61, 273\u2013283 (2020).","journal-title":"Yonsei Med. J."},{"key":"751_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s42466-021-00162-9","volume":"4","author":"S Jablonka","year":"2022","unstructured":"Jablonka, S., Hennlein, L. & Sendtner, M. Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders. Neurol. Res. Pract. 4, 2 (2022).","journal-title":"Neurol. Res. Pract."},{"key":"751_CR28","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3389\/fonc.2020.01387","volume":"10","author":"F Uddin","year":"2020","unstructured":"Uddin, F., Rudin, C. M. & Sen, T. CRISPR gene therapy: applications, limitations, and implications for the future. Front. Oncol. 10, 1387 (2020).","journal-title":"Front. Oncol."},{"key":"751_CR29","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore, J. D. et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N. Engl. J. Med. 385, 493\u2013502 (2021).","journal-title":"N. Engl. J. Med."},{"key":"751_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s42466-020-00075-z","volume":"2","author":"D Brenner","year":"2020","unstructured":"Brenner, D., Ludolph, A. C. & Weishaupt, J. H. Gene specific therapies \u2013 the next therapeutic milestone in neurology. Neurol. Res. Pract. 2, 25 (2020).","journal-title":"Neurol. Res. Pract."},{"key":"751_CR31","doi-asserted-by":"publisher","first-page":"100103","DOI":"10.1016\/j.xplc.2020.100103","volume":"1","author":"YC Xu","year":"2020","unstructured":"Xu, Y. C. & Guo, Y. L. Less is more, natural loss-of-function mutation is a strategy for adaptation. Plant. Commun. 1, 100103 (2020).","journal-title":"Plant. Commun."},{"key":"751_CR32","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nrd.2018.158","volume":"17","author":"BE Deverman","year":"2018","unstructured":"Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M. & Sah, D. W. Y. Gene therapy for neurological disorders: progress and prospects. Nat. Rev. Drug. Discov. 17, 767 (2018).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"751_CR33","doi-asserted-by":"publisher","first-page":"724","DOI":"10.3389\/fphar.2019.00724","volume":"10","author":"S Ingusci","year":"2019","unstructured":"Ingusci, S., Verlengia, G., Soukupova, M., Zucchini, S. & Simonato, M. Gene therapy tools for brain diseases. Front. Pharmacol. 10, 724 (2019).","journal-title":"Front. Pharmacol."},{"key":"751_CR34","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","volume":"31","author":"MF Naso","year":"2017","unstructured":"Naso, M. F., Tomkowicz, B., Perry, W. L. & Strohl, W. R. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs 31, 317\u2013334 (2017).","journal-title":"BioDrugs"},{"key":"751_CR35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s11689-018-9234-0","volume":"10","author":"EA Lykken","year":"2018","unstructured":"Lykken, E. A., Shyng, C., Edwards, R. J., Rozenberg, A. & Gray, S. J. Recent progress and considerations for AAV gene therapies targeting the central nervous system. J. Neurodev. Disord. 10, 16 (2018).","journal-title":"J. Neurodev. Disord."},{"key":"751_CR36","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.ymthe.2005.11.015","volume":"13","author":"CN Cearley","year":"2006","unstructured":"Cearley, C. N. & Wolfe, J. H. Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol. Ther. 13, 528\u2013537 (2006).","journal-title":"Mol. Ther."},{"key":"751_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nbt.1515","volume":"27","author":"KD Foust","year":"2009","unstructured":"Foust, K. D. et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27, 59\u201365 (2009).","journal-title":"Nat. Biotechnol."},{"key":"751_CR38","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/mt.2011.72","volume":"19","author":"SJ Gray","year":"2011","unstructured":"Gray, S. J. et al. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol. Ther. 19, 1058\u20131069 (2011).","journal-title":"Mol. Ther."},{"key":"751_CR39","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.neuron.2019.02.017","volume":"101","author":"E Hudry","year":"2019","unstructured":"Hudry, E. & Vandenberghe, L. H. Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron 101, 839\u2013862 (2019).","journal-title":"Neuron"},{"key":"751_CR40","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/978-1-4939-9139-6_8","volume":"1950","author":"DJ Gessler","year":"2019","unstructured":"Gessler, D. J., Tai, P. W. L., Li, J. & Gao, G. Intravenous infusion of AAV for widespread gene delivery to the nervous system. Methods Mol. Biol. 1950, 143\u2013163 (2019).","journal-title":"Methods Mol. Biol."},{"key":"751_CR41","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","volume":"8","author":"P Colella","year":"2018","unstructured":"Colella, P., Ronzitti, G. & Mingozzi, F. Emerging issues in AAV-mediated in vivo gene therapy. Mol. Ther. Methods Clin. Dev. 8, 87\u2013104 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"751_CR42","doi-asserted-by":"publisher","first-page":"R3","DOI":"10.1093\/hmg\/ddz148","volume":"28","author":"C Domenger","year":"2019","unstructured":"Domenger, C. & Grimm, D. Next-generation AAV vectors \u2013 do not judge a virus (only) by its cover. Hum. Mol. Genet. 28, R3\u2013R14 (2019).","journal-title":"Hum. Mol. Genet."},{"key":"751_CR43","first-page":"49","volume":"19","author":"SK Powell","year":"2015","unstructured":"Powell, S. K., Rivera-Soto, R. & Gray, S. J. Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy. Discov. Med. 19, 49\u201357 (2015).","journal-title":"Discov. Med."},{"key":"751_CR44","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1089\/hum.2010.245","volume":"22","author":"SJ Gray","year":"2011","unstructured":"Gray, S. J. et al. Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum. Gene Ther. 22, 1143\u20131153 (2011).","journal-title":"Hum. Gene Ther."},{"key":"751_CR45","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.ymthe.2003.08.021","volume":"8","author":"H Fu","year":"2003","unstructured":"Fu, H. et al. Self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain. Mol. Ther. 8, 911\u2013917 (2003).","journal-title":"Mol. Ther."},{"key":"751_CR46","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ymthe.2006.03.014","volume":"14","author":"K Inagaki","year":"2006","unstructured":"Inagaki, K. et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol. Ther. 14, 45\u201353 (2006).","journal-title":"Mol. Ther."},{"key":"751_CR47","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/sj.gt.3301529","volume":"8","author":"R Xu","year":"2001","unstructured":"Xu, R. et al. Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes. Gene Ther. 8, 1323\u20131332 (2001).","journal-title":"Gene Ther."},{"key":"751_CR48","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41434-020-0169-1","volume":"28","author":"B Nieuwenhuis","year":"2021","unstructured":"Nieuwenhuis, B. et al. Optimization of adeno-associated viral vector-mediated transduction of the corticospinal tract: comparison of four promoters. Gene Ther. 28, 56\u201374 (2021).","journal-title":"Gene Ther."},{"key":"751_CR49","doi-asserted-by":"publisher","first-page":"15055","DOI":"10.1038\/mtm.2015.55","volume":"3","author":"V Lukashchuk","year":"2016","unstructured":"Lukashchuk, V., Lewis, K. E., Coldicott, I., Grierson, A. J. & Azzouz, M. AAV9-mediated central nervous system-targeted gene delivery via cisterna magna route in mice. Mol. Ther. Methods Clin. Dev. 3, 15055 (2016).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"751_CR50","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nbt.3440","volume":"34","author":"BE Deverman","year":"2016","unstructured":"Deverman, B. E. et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204\u2013209 (2016).","journal-title":"Nat. Biotechnol."},{"key":"751_CR51","first-page":"116","volume":"9","author":"KL Jackson","year":"2016","unstructured":"Jackson, K. L., Dayton, R. D., Deverman, B. E. & Klein, R. L. Better targeting, better efficiency for wide-scale neuronal transduction with the synapsin promoter and AAV-PHP.B. Front. Mol. Neurosci. 9, 116 (2016).","journal-title":"Front. Mol. Neurosci."},{"key":"751_CR52","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/mt.2008.171","volume":"16","author":"DM McCarty","year":"2008","unstructured":"McCarty, D. M. Self-complementary AAV vectors; advances and applications. Mol. Ther. 16, 1648\u20131656 (2008).","journal-title":"Mol. Ther."},{"key":"751_CR53","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/sj.gt.3301514","volume":"8","author":"DM McCarty","year":"2001","unstructured":"McCarty, D. M., Monahan, P. E. & Samulski, R. J. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 8, 1248\u20131254 (2001).","journal-title":"Gene Ther."},{"key":"751_CR54","doi-asserted-by":"crossref","unstructured":"High-dose AAV gene therapy deaths. Nat. Biotechnol. 38, 910 (2020).","DOI":"10.1038\/s41587-020-0642-9"},{"key":"751_CR55","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1089\/hum.2021.29182.bfs","volume":"32","author":"A Philippidis","year":"2021","unstructured":"Philippidis, A. Fourth boy dies in clinical trial of Astellas\u2019 AT132. Hum. Gene Ther. 32, 1008\u20131010 (2021).","journal-title":"Hum. Gene Ther."},{"key":"751_CR56","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1089\/hum.2009.182","volume":"21","author":"S Boutin","year":"2010","unstructured":"Boutin, S. et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 21, 704\u2013712 (2010).","journal-title":"Hum. Gene Ther."},{"key":"751_CR57","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1086\/595830","volume":"199","author":"R Calcedo","year":"2009","unstructured":"Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J. & Wilson, J. M. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J. Infect. Dis. 199, 381\u2013390 (2009).","journal-title":"J. Infect. Dis."},{"key":"751_CR58","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.omtm.2019.05.014","volume":"14","author":"A Kruzik","year":"2019","unstructured":"Kruzik, A. et al. Prevalence of anti-adeno-associated virus immune responses in international cohorts of healthy donors. Mol. Ther. Methods Clin. Dev. 14, 126\u2013133 (2019).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"751_CR59","doi-asserted-by":"publisher","first-page":"658399","DOI":"10.3389\/fimmu.2021.658399","volume":"12","author":"T Weber","year":"2021","unstructured":"Weber, T. Anti-AAV antibodies in AAV gene therapy: current challenges and possible solutions. Front. Immunol. 12, 658399 (2021).","journal-title":"Front. Immunol."},{"key":"751_CR60","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1128\/CVI.05107-11","volume":"18","author":"R Calcedo","year":"2011","unstructured":"Calcedo, R. et al. Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin. Vaccin. Immunol. 18, 1586\u20131588 (2011).","journal-title":"Clin. Vaccin. Immunol."},{"key":"751_CR61","doi-asserted-by":"publisher","first-page":"103658","DOI":"10.1016\/j.cellimm.2017.05.006","volume":"342","author":"RW Herzog","year":"2019","unstructured":"Herzog, R. W. Complexity of immune responses to AAV transgene products \u2013 example of factor IX. Cell Immunol. 342, 103658 (2019).","journal-title":"Cell Immunol."},{"key":"751_CR62","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","volume":"122","author":"F Mingozzi","year":"2013","unstructured":"Mingozzi, F. & High, K. A. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122, 23\u201336 (2013).","journal-title":"Blood"},{"key":"751_CR63","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.addr.2021.01.017","volume":"170","author":"EA Chowdhury","year":"2021","unstructured":"Chowdhury, E. A. et al. Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic\/pharmacodynamic (PK\/PD) models. Adv. Drug. Deliv. Rev. 170, 214\u2013237 (2021).","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"751_CR64","doi-asserted-by":"publisher","first-page":"15540","DOI":"10.1021\/bi048284d","volume":"43","author":"B Vincents","year":"2004","unstructured":"Vincents, B., von Pawel-Rammingen, U., Bjorck, L. & Abrahamson, M. Enzymatic characterization of the streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease with strict specificity for IgG cleavage due to exosite binding. Biochemistry 43, 15540\u201315549 (2004).","journal-title":"Biochemistry"},{"key":"751_CR65","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.139881","volume":"5","author":"ZC Elmore","year":"2020","unstructured":"Elmore, Z. C., Oh, D. K., Simon, K. E., Fanous, M. M. & Asokan, A. Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme. JCI Insight 5, e139881 (2020).","journal-title":"JCI Insight"},{"key":"751_CR66","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","volume":"26","author":"C Leborgne","year":"2020","unstructured":"Leborgne, C. et al. IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies. Nat. Med. 26, 1096\u20131101 (2020).","journal-title":"Nat. Med."},{"key":"751_CR67","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1375","volume":"11","author":"I Ros-Ga\u00f1\u00e1n","year":"2022","unstructured":"Ros-Ga\u00f1\u00e1n, I. et al. Optimising the IgG-degrading enzyme treatment regimen for enhanced adeno-associated virus transduction in the presence of neutralising antibodies. Clin. Transl. Immunol. 11, e1375 (2022).","journal-title":"Clin. Transl. Immunol."},{"key":"751_CR68","doi-asserted-by":"publisher","first-page":"798","DOI":"10.3390\/biom10050798","volume":"10","author":"I Srejovic","year":"2020","unstructured":"Srejovic, I. et al. Galectin-3: roles in neurodevelopment, neuroinflammation, and behavior. Biomolecules 10, 798 (2020).","journal-title":"Biomolecules"},{"key":"751_CR69","doi-asserted-by":"publisher","first-page":"6620","DOI":"10.1128\/JVI.00297-12","volume":"86","author":"J Denard","year":"2012","unstructured":"Denard, J. et al. Human galectin 3 binding protein interacts with recombinant adeno-associated virus type 6. J. Virol. 86, 6620\u20136631 (2012).","journal-title":"J. Virol."},{"key":"751_CR70","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.omtm.2018.08.001","volume":"10","author":"J Denard","year":"2018","unstructured":"Denard, J. et al. AAV-8 and AAV-9 vectors cooperate with serum proteins differently than AAV-1 and AAV-6. Mol. Ther. Methods Clin. Dev. 10, 291\u2013302 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"751_CR71","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.3390\/ijms20184388","volume":"20","author":"M Cappella","year":"2019","unstructured":"Cappella, M., Ciotti, C., Cohen-Tannoudji, M. & Biferi, M. G. Gene therapy for ALS \u2013 a perspective. Int. J. Mol. Sci. 20, 4388 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"751_CR72","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1517\/14712598.2015.1044894","volume":"15","author":"JM Scarrott","year":"2015","unstructured":"Scarrott, J. M., Herranz-Mart\u00edn, S., Alrafiah, A. R., Shaw, P. J. & Azzouz, M. Current developments in gene therapy for amyotrophic lateral sclerosis. Expert. Opin. Biol. Ther. 15, 935\u2013947 (2015).","journal-title":"Expert. Opin. Biol. Ther."},{"key":"751_CR73","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1172\/JCI99081","volume":"128","author":"A McCampbell","year":"2018","unstructured":"McCampbell, A. et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J. Clin. Invest. 128, 3558\u20133567 (2018).","journal-title":"J. Clin. Invest."},{"key":"751_CR74","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2003715","volume":"383","author":"T Miller","year":"2020","unstructured":"Miller, T. et al. Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N. Engl. J. Med. 383, 109\u2013119 (2020).","journal-title":"N. Engl. J. Med."},{"key":"751_CR75","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller, T. M. et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N. Engl. J. Med. 387, 1099\u20131110 (2022).","journal-title":"N. Engl. J. Med."},{"key":"751_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/d41591-019-00013-w","author":"C Arnold","year":"2019","unstructured":"Arnold, C. Tailored treatment for ALS poised to move ahead. Nat. Med. https:\/\/doi.org\/10.1038\/d41591-019-00013-w (2019).","journal-title":"Nat. Med."},{"key":"751_CR77","unstructured":"Biogen. Biogen and Ionis announce topline phase 1 study results of investigational drug in C9orf72 amyotrophic lateral sclerosis. Biogen https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-and-ionis-announce-topline-phase-1-study-results (2022)."},{"key":"751_CR78","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/1061186X.2019.1630415","volume":"28","author":"SA Pena","year":"2020","unstructured":"Pena, S. A. et al. Gene therapy for neurological disorders: challenges and recent advancements. J. Drug. Target. 28, 111\u2013128 (2020).","journal-title":"J. Drug. Target."},{"key":"751_CR79","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/14737175.2017.1287565","volume":"17","author":"MS Tora","year":"2017","unstructured":"Tora, M. S., Keifer, O. P., Lamanna, J. J. & Boulis, N. M. The challenges of developing a gene therapy for amyotrophic lateral sclerosis. Expert. Rev. Neurother. 17, 323\u2013325 (2017).","journal-title":"Expert. Rev. Neurother."},{"key":"751_CR80","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13024-020-00383-7","volume":"15","author":"X Tang","year":"2020","unstructured":"Tang, X. et al. Divergence, convergence, and therapeutic implications: a cell biology perspective of C9ORF72-ALS\/FTD. Mol. Neurodegener. 15, 34 (2020).","journal-title":"Mol. Neurodegener."},{"key":"751_CR81","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1097\/WCO.0000000000000984","volume":"34","author":"GM Hautbergue","year":"2021","unstructured":"Hautbergue, G. M., Cleary, J. D., Guo, S. & Ranum, L. P. W. Therapeutic strategies for C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia. Curr. Opin. Neurol. 34, 748\u2013755 (2021).","journal-title":"Curr. Opin. Neurol."},{"key":"751_CR82","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrn3121","volume":"13","author":"EB Lee","year":"2011","unstructured":"Lee, E. B., Lee, V. M. & Trojanowski, J. Q. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat. Rev. Neurosci. 13, 38\u201350 (2011).","journal-title":"Nat. Rev. Neurosci."},{"key":"751_CR83","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40478-019-0658-x","volume":"7","author":"H An","year":"2019","unstructured":"An, H. et al. ALS-linked FUS mutations confer loss and gain of function in the nucleus by promoting excessive formation of dysfunctional paraspeckles. Acta Neuropathol. Commun. 7, 7 (2019).","journal-title":"Acta Neuropathol. Commun."},{"key":"751_CR84","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.brainres.2018.01.015","volume":"1693","author":"K Weskamp","year":"2018","unstructured":"Weskamp, K. & Barmada, S. J. TDP43 and RNA instability in amyotrophic lateral sclerosis. Brain Res. 1693, 67\u201374 (2018).","journal-title":"Brain Res."},{"key":"751_CR85","doi-asserted-by":"publisher","first-page":"4705","DOI":"10.3390\/ijms22094705","volume":"22","author":"A Wood","year":"2021","unstructured":"Wood, A., Gurfinkel, Y., Polain, N., Lamont, W. & Lyn Rea, S. Molecular mechanisms underlying TDP-43 pathology in cellular and animal models of ALS and FTLD. Int. J. Mol. Sci. 22, 4705 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"751_CR86","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s12031-015-0695-2","volume":"58","author":"C Benkler","year":"2016","unstructured":"Benkler, C., Barhum, Y., Ben-Zur, T. & Offen, D. Multifactorial gene therapy enhancing the glutamate uptake system and reducing oxidative stress delays symptom onset and prolongs survival in the SOD1-G93A ALS mouse model. J. Mol. Neurosci. 58, 46\u201358 (2016).","journal-title":"J. Mol. Neurosci."},{"key":"751_CR87","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-3-319-55769-4_6","volume":"16","author":"LT Rosenblum","year":"2017","unstructured":"Rosenblum, L. T. & Trotti, D. EAAT2 and the molecular signature of amyotrophic lateral sclerosis. Adv. Neurobiol. 16, 117\u2013136 (2017).","journal-title":"Adv. Neurobiol."},{"key":"751_CR88","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/mus.26801","volume":"62","author":"NA Goyal","year":"2020","unstructured":"Goyal, N. A. et al. Addressing heterogeneity in amyotrophic lateral sclerosis clinical trials. Muscle Nerve 62, 156\u2013166 (2020).","journal-title":"Muscle Nerve"},{"key":"751_CR89","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/21678421.2020.1779298","volume":"21","author":"C Bendotti","year":"2020","unstructured":"Bendotti, C. et al. Focus on the heterogeneity of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 21, 485\u2013495 (2020).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"751_CR90","doi-asserted-by":"publisher","first-page":"562758","DOI":"10.3389\/fgene.2020.562758","volume":"11","author":"Q Yang","year":"2020","unstructured":"Yang, Q., Jiao, B. & Shen, L. The development of C9orf72-related amyotrophic lateral sclerosis and frontotemporal dementia disorders. Front. Genet. 11, 562758 (2020).","journal-title":"Front. Genet."},{"key":"751_CR91","doi-asserted-by":"publisher","first-page":"661447","DOI":"10.3389\/fncel.2021.661447","volume":"15","author":"J Smeyers","year":"2021","unstructured":"Smeyers, J., Banchi, E. G. & Latouche, M. C9ORF72: what it is, what it does, and why it matters. Front. Cell Neurosci. 15, 661447 (2021).","journal-title":"Front. Cell Neurosci."},{"key":"751_CR92","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fnmol.2019.00025","volume":"12","author":"A Prasad","year":"2019","unstructured":"Prasad, A., Bharathi, V., Sivalingam, V., Girdhar, A. & Patel, B. K. Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis. Front. Mol. Neurosci. 12, 25 (2019).","journal-title":"Front. Mol. Neurosci."},{"key":"751_CR93","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13024-020-00397-1","volume":"15","author":"TR Suk","year":"2020","unstructured":"Suk, T. R. & Rousseaux, M. W. C. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol. Neurodegener. 15, 45 (2020).","journal-title":"Mol. Neurodegener."},{"key":"751_CR94","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1126\/science.aaa3650","volume":"347","author":"ET Cirulli","year":"2015","unstructured":"Cirulli, E. T. et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science 347, 1436\u20131441 (2015).","journal-title":"Science"},{"key":"751_CR95","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nn.4000","volume":"18","author":"A Freischmidt","year":"2015","unstructured":"Freischmidt, A. et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci. 18, 631\u2013636 (2015).","journal-title":"Nat. Neurosci."},{"key":"751_CR96","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/abbs\/gmaa051","volume":"52","author":"R Zhou","year":"2020","unstructured":"Zhou, R., Zhang, Q. & Xu, P. TBK1, a central kinase in innate immune sensing of nucleic acids and beyond. Acta Biochim. Biophys. Sin. 52, 757\u2013767 (2020).","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"751_CR97","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.matbio.2021.01.004","volume":"100\u2013101","author":"L Herhaus","year":"2021","unstructured":"Herhaus, L. TBK1 (TANK-binding kinase 1)-mediated regulation of autophagy in health and disease. Matrix Biol. 100\u2013101, 84\u201398 (2021).","journal-title":"Matrix Biol."},{"key":"751_CR98","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1084\/jem.20040528","volume":"199","author":"AK Perry","year":"2004","unstructured":"Perry, A. K., Chow, E. K., Goodnough, J. B., Yeh, W. C. & Cheng, G. Differential requirement for TANK-binding kinase-1 in type I interferon responses to toll-like receptor activation and viral infection. J. Exp. Med. 199, 1651\u20131658 (2004).","journal-title":"J. Exp. Med."},{"key":"751_CR99","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.febslet.2013.01.052","volume":"587","author":"W Zhao","year":"2013","unstructured":"Zhao, W. Negative regulation of TBK1-mediated antiviral immunity. FEBS Lett. 587, 542\u2013548 (2013).","journal-title":"FEBS Lett."},{"key":"751_CR100","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.4049\/jimmunol.0802466","volume":"182","author":"AK Miyahira","year":"2009","unstructured":"Miyahira, A. K., Shahangian, A., Hwang, S., Sun, R. & Cheng, G. TANK-binding kinase-1 plays an important role during in vitro and in vivo type I IFN responses to DNA virus infections. J. Immunol. 182, 2248\u20132257 (2009).","journal-title":"J. Immunol."},{"key":"751_CR101","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-017-0287-x","volume":"10","author":"JA Oakes","year":"2017","unstructured":"Oakes, J. A., Davies, M. C. & Collins, M. O. TBK1: a new player in ALS linking autophagy and neuroinflammation. Mol. Brain 10, 5 (2017).","journal-title":"Mol. Brain"},{"key":"751_CR102","doi-asserted-by":"publisher","first-page":"6694","DOI":"10.1093\/emboj\/18.23.6694","volume":"18","author":"JL Pomerantz","year":"1999","unstructured":"Pomerantz, J. L. & Baltimore, D. NF-\u03baB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase. EMBO J. 18, 6694\u20136704 (1999).","journal-title":"EMBO J."},{"key":"751_CR103","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/ni.2423","volume":"13","author":"J Jin","year":"2012","unstructured":"Jin, J. et al. The kinase TBK1 controls IgA class switching by negatively regulating noncanonical NF-\u03baB signaling. Nat. Immunol. 13, 1101\u20131109 (2012).","journal-title":"Nat. Immunol."},{"key":"751_CR104","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.cell.2018.01.007","volume":"172","author":"P Zhao","year":"2018","unstructured":"Zhao, P. et al. TBK1 at the crossroads of inflammation and energy homeostasis in adipose tissue. Cell 172, 731\u2013743.e12 (2018).","journal-title":"Cell"},{"key":"751_CR105","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.molcel.2015.08.016","volume":"60","author":"JM Heo","year":"2015","unstructured":"Heo, J. M., Ordureau, A., Paulo, J. A., Rinehart, J. & Harper, J. W. The PINK1-PARKIN mitochondrial ubiquitylation pathway drives a program of OPTN\/NDP52 recruitment and TBK1 activation to promote mitophagy. Mol. Cell 60, 7\u201320 (2015).","journal-title":"Mol. Cell"},{"key":"751_CR106","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3390\/cells9020381","volume":"9","author":"E Vicencio","year":"2020","unstructured":"Vicencio, E. et al. Implications of selective autophagy dysfunction for ALS pathology. Cells 9, 381 (2020).","journal-title":"Cells"},{"key":"751_CR107","doi-asserted-by":"publisher","first-page":"191.e11","DOI":"10.1016\/j.neurobiolaging.2015.12.022","volume":"40","author":"PC Tsai","year":"2016","unstructured":"Tsai, P. C. et al. Mutational analysis of TBK1 in Taiwanese patients with amyotrophic lateral sclerosis. Neurobiol. Aging 40, 191.e11\u2013191.e16 (2016).","journal-title":"Neurobiol. Aging"},{"key":"751_CR108","doi-asserted-by":"publisher","first-page":"3334.e1","DOI":"10.1016\/j.neurobiolaging.2015.08.013","volume":"36","author":"KL Williams","year":"2015","unstructured":"Williams, K. L. et al. Novel TBK1 truncating mutation in a familial amyotrophic lateral sclerosis patient of Chinese origin. Neurobiol. Aging 36, 3334.e1\u20133334.e5 (2015).","journal-title":"Neurobiol. Aging"},{"key":"751_CR109","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1080\/21678421.2016.1183681","volume":"17","author":"S Shu","year":"2016","unstructured":"Shu, S. et al. Screening of the TBK1 gene in familial and sporadic amyotrophic lateral sclerosis patients of Chinese origin. Amyotroph. Lateral Scler. Frontotemporal Degener. 17, 605\u2013607 (2016).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"751_CR110","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1136\/jnnp-2017-316174","volume":"88","author":"L Pozzi","year":"2017","unstructured":"Pozzi, L. et al. TBK1 mutations in Italian patients with amyotrophic lateral sclerosis: genetic and functional characterisation. J. Neurol. Neurosurg. Psychiatry 88, 869\u2013875 (2017).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"751_CR111","doi-asserted-by":"publisher","first-page":"266.e1","DOI":"10.1016\/j.neurobiolaging.2018.06.015","volume":"71","author":"M de Majo","year":"2018","unstructured":"de Majo, M. et al. ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function. Neurobiol. Aging 71, 266.e1\u2013266.e10 (2018).","journal-title":"Neurobiol. Aging"},{"key":"751_CR112","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/nan.12578","volume":"46","author":"M Weinreich","year":"2020","unstructured":"Weinreich, M. et al. Neuropathological characterization of a novel TANK binding kinase (TBK1) gene loss of function mutation associated with amyotrophic lateral sclerosis. Neuropathol. Appl. Neurobiol. 46, 279\u2013291 (2020).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"751_CR113","doi-asserted-by":"publisher","first-page":"24517","DOI":"10.1073\/pnas.1915732116","volume":"116","author":"J Ye","year":"2019","unstructured":"Ye, J. et al. Effects of ALS-associated TANK binding kinase 1 mutations on protein-protein interactions and kinase activity. Proc. Natl Acad. Sci. USA 116, 24517\u201324526 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"751_CR114","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1212\/WNL.0000000000002220","volume":"85","author":"I Gijselinck","year":"2015","unstructured":"Gijselinck, I. et al. Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort. Neurology 85, 2116\u20132125 (2015).","journal-title":"Neurology"},{"key":"751_CR115","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00401-015-1436-x","volume":"130","author":"C Pottier","year":"2015","unstructured":"Pottier, C. et al. Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta Neuropathol. 130, 77\u201392 (2015).","journal-title":"Acta Neuropathol."},{"key":"751_CR116","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/humu.23161","volume":"38","author":"J van der Zee","year":"2017","unstructured":"van der Zee, J. et al. TBK1 mutation spectrum in an extended European patient cohort with frontotemporal dementia and amyotrophic lateral sclerosis. Hum. Mutat. 38, 297\u2013309 (2017).","journal-title":"Hum. Mutat."},{"key":"751_CR117","doi-asserted-by":"publisher","first-page":"103539","DOI":"10.1016\/j.mcn.2020.103539","volume":"108","author":"AD Foster","year":"2020","unstructured":"Foster, A. D. et al. ALS-associated TBK1 variant p.G175S is defective in phosphorylation of p62 and impacts TBK1-mediated signalling and TDP-43 autophagic degradation. Mol. Cell Neurosci. 108, 103539 (2020).","journal-title":"Mol. Cell Neurosci."},{"key":"751_CR118","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2025053118","volume":"118","author":"O Harding","year":"2021","unstructured":"Harding, O. et al. ALS- and FTD-associated missense mutations in TBK1 differentially disrupt mitophagy. Proc. Natl Acad. Sci. USA 118, e2025053118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"751_CR119","doi-asserted-by":"publisher","first-page":"4976","DOI":"10.1093\/emboj\/19.18.4976","volume":"19","author":"M Bonnard","year":"2000","unstructured":"Bonnard, M. et al. Deficiency of T2K leads to apoptotic liver degeneration and impaired NF-\u03baB-dependent gene transcription. EMBO J. 19, 4976\u20134985 (2000).","journal-title":"EMBO J."},{"key":"751_CR120","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1084\/jem.20180729","volume":"216","author":"D Brenner","year":"2019","unstructured":"Brenner, D. et al. Heterozygous Tbk1 loss has opposing effects in early and late stages of ALS in mice. J. Exp. Med. 216, 267\u2013278 (2019).","journal-title":"J. Exp. Med."},{"key":"751_CR121","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.neuron.2020.03.005","volume":"106","author":"V Gerbino","year":"2020","unstructured":"Gerbino, V. et al. The loss of TBK1 kinase activity in motor neurons or in all cell types differentially impacts ALS disease progression in SOD1 mice. Neuron 106, 789\u2013805.e5 (2020).","journal-title":"Neuron"},{"key":"751_CR122","doi-asserted-by":"publisher","first-page":"fcaa133","DOI":"10.1093\/braincomms\/fcaa133","volume":"2","author":"C Bruno","year":"2020","unstructured":"Bruno, C. et al. Haploinsufficiency of TANK-binding kinase 1 prepones age-associated neuroinflammatory changes without causing motor neuron degeneration in aged mice. Brain Commun. 2, fcaa133 (2020).","journal-title":"Brain Commun."},{"key":"751_CR123","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.18632\/aging.101936","volume":"11","author":"W Duan","year":"2019","unstructured":"Duan, W. et al. Deletion of Tbk1 disrupts autophagy and reproduces behavioral and locomotor symptoms of FTD-ALS in mice. Aging 11, 2457\u20132476 (2019).","journal-title":"Aging"},{"key":"751_CR124","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.exer.2015.06.029","volume":"144","author":"H Ying","year":"2016","unstructured":"Ying, H. & Yue, B. Y. Optineurin: the autophagy connection. Exp. Eye Res. 144, 73\u201380 (2016).","journal-title":"Exp. Eye Res."},{"key":"751_CR125","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/iub.1355","volume":"67","author":"M Bansal","year":"2015","unstructured":"Bansal, M., Swarup, G. & Balasubramanian, D. Functional analysis of optineurin and some of its disease-associated mutants. IUBMB Life 67, 120\u2013128 (2015).","journal-title":"IUBMB Life"},{"key":"751_CR126","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00441-014-1968-8","volume":"358","author":"C Sippl","year":"2014","unstructured":"Sippl, C., Zeilbeck, L. F., Fuchshofer, R. & Tamm, E. R. Optineurin associates with the podocyte Golgi complex to maintain its structure. Cell Tissue Res. 358, 567\u2013583 (2014).","journal-title":"Cell Tissue Res."},{"key":"751_CR127","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1083\/jcb.200501162","volume":"169","author":"DA Sahlender","year":"2005","unstructured":"Sahlender, D. A. et al. Optineurin links myosin VI to the Golgi complex and is involved in Golgi organization and exocytosis. J. Cell Biol. 169, 285\u2013295 (2005).","journal-title":"J. Cell Biol."},{"key":"751_CR128","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.2353\/ajpath.2006.060400","volume":"169","author":"BC Park","year":"2006","unstructured":"Park, B. C., Shen, X., Samaraweera, M. & Yue, B. Y. Studies of optineurin, a glaucoma gene: Golgi fragmentation and cell death from overexpression of wild-type and mutant optineurin in two ocular cell types. Am. J. Pathol. 169, 1976\u20131989 (2006).","journal-title":"Am. J. Pathol."},{"key":"751_CR129","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1080\/21678421.2016.1218517","volume":"18","author":"JA Fifita","year":"2017","unstructured":"Fifita, J. A. et al. A novel amyotrophic lateral sclerosis mutation in OPTN induces ER stress and Golgi fragmentation in vitro. Amyotroph. Lateral Scler. Frontotemporal Degener. 18, 126\u2013133 (2017).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"751_CR130","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1002\/acn3.50928","volume":"6","author":"SM Feng","year":"2019","unstructured":"Feng, S. M. et al. Novel mutation in optineurin causing aggressive ALS+\/-frontotemporal dementia. Ann. Clin. Transl. Neurol. 6, 2377\u20132383 (2019).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"751_CR131","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1242\/jcs.114926","volume":"126","author":"J Korac","year":"2013","unstructured":"Korac, J. et al. Ubiquitin-independent function of optineurin in autophagic clearance of protein aggregates. J. Cell Sci. 126, 580\u2013592 (2013).","journal-title":"J. Cell Sci."},{"key":"751_CR132","doi-asserted-by":"publisher","first-page":"103525","DOI":"10.1016\/j.resp.2020.103525","volume":"282","author":"AL McCall","year":"2020","unstructured":"McCall, A. L. et al. Respiratory pathology in the Optn\u2212\/\u2212 mouse model of amyotrophic lateral sclerosis. Respir. Physiol. Neurobiol. 282, 103525 (2020).","journal-title":"Respir. Physiol. Neurobiol."},{"key":"751_CR133","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nature08971","volume":"465","author":"H Maruyama","year":"2010","unstructured":"Maruyama, H. et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 465, 223\u2013226 (2010).","journal-title":"Nature"},{"key":"751_CR134","doi-asserted-by":"publisher","first-page":"208.e1","DOI":"10.1016\/j.neurobiolaging.2011.07.001","volume":"33","author":"Z T\u00fcmer","year":"2012","unstructured":"T\u00fcmer, Z. et al. Novel heterozygous nonsense mutation of the OPTN gene segregating in a Danish family with ALS. Neurobiol. Aging 33, 208.e1\u2013208.e5 (2012).","journal-title":"Neurobiol. Aging"},{"key":"751_CR135","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1212\/WNL.0000000000002334","volume":"86","author":"O Goldstein","year":"2016","unstructured":"Goldstein, O. et al. OPTN 691_692insAG is a founder mutation causing recessive ALS and increased risk in heterozygotes. Neurology 86, 446\u2013453 (2016).","journal-title":"Neurology"},{"key":"751_CR136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2021.05.009","volume":"106","author":"M Gotkine","year":"2021","unstructured":"Gotkine, M. et al. A recessive S174X mutation in optineurin causes amyotrophic lateral sclerosis through a loss of function via allele-specific nonsense-mediated decay. Neurobiol. Aging 106, 1\u20136 (2021).","journal-title":"Neurobiol. Aging"},{"key":"751_CR137","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/ajmg.b.32606","volume":"177","author":"SMK Farhan","year":"2018","unstructured":"Farhan, S. M. K., Gendron, T. F., Petrucelli, L., Hegele, R. A. & Strong, M. J. OPTN p.Met468Arg and ATXN2 intermediate length polyQ extension in families with C9orf72 mediated amyotrophic lateral sclerosis and frontotemporal dementia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 177, 75\u201385 (2018).","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"751_CR138","doi-asserted-by":"publisher","first-page":"557.e11","DOI":"10.1016\/j.neurobiolaging.2010.11.005","volume":"32","author":"S Millecamps","year":"2011","unstructured":"Millecamps, S. et al. Screening of OPTN in French familial amyotrophic lateral sclerosis. Neurobiol. Aging 32, 557.e11\u2013557.e13 (2011).","journal-title":"Neurobiol. Aging"},{"key":"751_CR139","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/neup.12051","volume":"34","author":"M Kamada","year":"2014","unstructured":"Kamada, M. et al. Clinicopathologic features of autosomal recessive amyotrophic lateral sclerosis associated with optineurin mutation. Neuropathology 34, 64\u201370 (2014).","journal-title":"Neuropathology"},{"key":"751_CR140","doi-asserted-by":"publisher","first-page":"685","DOI":"10.4161\/auto.36098","volume":"11","author":"WC Shen","year":"2015","unstructured":"Shen, W. C., Li, H. Y., Chen, G. C., Chern, Y. & Tu, P. H. Mutations in the ubiquitin-binding domain of OPTN\/optineurin interfere with autophagy-mediated degradation of misfolded proteins by a dominant-negative mechanism. Autophagy 11, 685\u2013700 (2015).","journal-title":"Autophagy"},{"key":"751_CR141","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1093\/hmg\/ddv126","volume":"24","author":"V Sundaramoorthy","year":"2015","unstructured":"Sundaramoorthy, V. et al. Defects in optineurin- and myosin VI-mediated cellular trafficking in amyotrophic lateral sclerosis. Hum. Mol. Genet. 24, 3830\u20133846 (2015).","journal-title":"Hum. Mol. Genet."},{"key":"751_CR142","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.50260","volume":"9","author":"CS Evans","year":"2020","unstructured":"Evans, C. S. & Holzbaur, E. L. Degradation of engulfed mitochondria is rate-limiting in optineurin-mediated mitophagy in neurons. Elife 9, e50260 (2020).","journal-title":"Elife"},{"key":"751_CR143","doi-asserted-by":"publisher","first-page":"E3349","DOI":"10.1073\/pnas.1523810113","volume":"113","author":"AS Moore","year":"2016","unstructured":"Moore, A. S. & Holzbaur, E. L. Dynamic recruitment and activation of ALS-associated TBK1 with its target optineurin are required for efficient mitophagy. Proc. Natl Acad. Sci. USA 113, E3349\u2013E3358 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"751_CR144","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12547","volume":"7","author":"S Nakazawa","year":"2016","unstructured":"Nakazawa, S. et al. Linear ubiquitination is involved in the pathogenesis of optineurin-associated amyotrophic lateral sclerosis. Nat. Commun. 7, 12547 (2016).","journal-title":"Nat. Commun."},{"key":"751_CR145","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/jnc.12326","volume":"126","author":"M Akizuki","year":"2013","unstructured":"Akizuki, M. et al. Optineurin suppression causes neuronal cell death via NF-\u03baB pathway. J. Neurochem. 126, 699\u2013704 (2013).","journal-title":"J. Neurochem."},{"key":"751_CR146","doi-asserted-by":"publisher","first-page":"15369","DOI":"10.1021\/bi034575v","volume":"42","author":"MJ Surpili","year":"2003","unstructured":"Surpili, M. J., Delben, T. M. & Kobarg, J. Identification of proteins that interact with the central coiled-coil region of the human protein kinase NEK1. Biochemistry 42, 15369\u201315376 (2003).","journal-title":"Biochemistry"},{"key":"751_CR147","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-05325-w","volume":"7","author":"TD Melo-Hanchuk","year":"2017","unstructured":"Melo-Hanchuk, T. D. et al. NEK1 kinase domain structure and its dynamic protein interactome after exposure to cisplatin. Sci. Rep. 7, 5445 (2017).","journal-title":"Sci. Rep."},{"key":"751_CR148","doi-asserted-by":"publisher","first-page":"255.e1","DOI":"10.1016\/j.neurobiolaging.2017.08.021","volume":"61","author":"HP Nguyen","year":"2018","unstructured":"Nguyen, H. P. et al. NEK1 genetic variability in a Belgian cohort of ALS and ALS-FTD patients. Neurobiol. Aging 61, 255.e1\u2013255.e7 (2018).","journal-title":"Neurobiol. Aging"},{"key":"751_CR149","first-page":"4423","volume":"125","author":"AM Fry","year":"2012","unstructured":"Fry, A. M., O\u2019Regan, L., Sabir, S. R. & Bayliss, R. Cell cycle regulation by the NEK family of protein kinases. J. Cell Sci. 125, 4423\u20134433 (2012).","journal-title":"J. Cell Sci."},{"key":"751_CR150","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4161\/cc.8.2.7551","volume":"8","author":"Y Chen","year":"2009","unstructured":"Chen, Y., Craigen, W. J. & Riley, D. J. Nek1 regulates cell death and mitochondrial membrane permeability through phosphorylation of VDAC1. Cell Cycle 8, 257\u2013267 (2009).","journal-title":"Cell Cycle"},{"key":"751_CR151","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.bbrc.2010.03.077","volume":"394","author":"Y Chen","year":"2010","unstructured":"Chen, Y., Gaczynska, M., Osmulski, P., Polci, R. & Riley, D. J. Phosphorylation by Nek1 regulates opening and closing of voltage dependent anion channel 1. Biochem. Biophys. Res. Commun. 394, 798\u2013803 (2010).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"751_CR152","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww033","volume":"139","author":"D Brenner","year":"2016","unstructured":"Brenner, D. et al. NEK1 mutations in familial amyotrophic lateral sclerosis. Brain 139, e28 (2016).","journal-title":"Brain"},{"key":"751_CR153","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/hmg\/ddab015","volume":"30","author":"S Lattante","year":"2021","unstructured":"Lattante, S. et al. Novel variants and cellular studies on patients\u2019 primary fibroblasts support a role for NEK1 missense variants in ALS pathogenesis. Hum. Mol. Genet. 30, 65\u201371 (2021).","journal-title":"Hum. Mol. Genet."},{"key":"751_CR154","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.scr.2018.06.005","volume":"30","author":"J Higelin","year":"2018","unstructured":"Higelin, J. et al. NEK1 loss-of-function mutation induces DNA damage accumulation in ALS patient-derived motoneurons. Stem Cell Res. 30, 150\u2013162 (2018).","journal-title":"Stem Cell Res."},{"key":"751_CR155","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/leu.2010.6","volume":"24","author":"LJ Mah","year":"2010","unstructured":"Mah, L. J., El-Osta, A. & Karagiannis, T. C. gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 24, 679\u2013686 (2010).","journal-title":"Leukemia"},{"key":"751_CR156","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1093\/brain\/awr148","volume":"134","author":"G Nicholson","year":"2011","unstructured":"Nicholson, G. et al. Distinctive genetic and clinical features of CMT4J: a severe neuropathy caused by mutations in the PI(3,5)P2 phosphatase FIG4. Brain 134, 1959\u20131971 (2011).","journal-title":"Brain"},{"key":"751_CR157","doi-asserted-by":"publisher","first-page":"561","DOI":"10.15252\/embj.201593564","volume":"35","author":"AL Marat","year":"2016","unstructured":"Marat, A. L. & Haucke, V. Phosphatidylinositol 3-phosphates \u2013 at the interface between cell signalling and membrane traffic. EMBO J. 35, 561\u2013579 (2016).","journal-title":"EMBO J."},{"key":"751_CR158","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ajhg.2008.12.010","volume":"84","author":"CY Chow","year":"2009","unstructured":"Chow, C. Y. et al. Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS. Am. J. Hum. Genet. 84, 85\u201388 (2009).","journal-title":"Am. J. Hum. Genet."},{"key":"751_CR159","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/ejhg.2016.186","volume":"25","author":"A Osmanovic","year":"2017","unstructured":"Osmanovic, A. et al. FIG4 variants in central European patients with amyotrophic lateral sclerosis: a whole-exome and targeted sequencing study. Eur. J. Hum. Genet. 25, 324\u2013331 (2017).","journal-title":"Eur. J. Hum. Genet."},{"key":"751_CR160","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1128\/EC.5.4.723-731.2006","volume":"5","author":"JE Duex","year":"2006","unstructured":"Duex, J. E., Nau, J. J., Kauffman, E. J. & Weisman, L. S. Phosphoinositide 5-phosphatase Fig 4p is required for both acute rise and subsequent fall in stress-induced phosphatidylinositol 3,5-bisphosphate levels. Eukaryot. Cell 5, 723\u2013731 (2006).","journal-title":"Eukaryot. Cell"},{"key":"751_CR161","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature05876","volume":"448","author":"CY Chow","year":"2007","unstructured":"Chow, C. Y. et al. Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4J. Nature 448, 68\u201372 (2007).","journal-title":"Nature"},{"key":"751_CR162","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002104","volume":"7","author":"GM Lenk","year":"2011","unstructured":"Lenk, G. M. et al. Pathogenic mechanism of the FIG4 mutation responsible for Charcot-Marie-Tooth disease CMT4J. PLoS Genet. 7, e1002104 (2011).","journal-title":"PLoS Genet."},{"key":"751_CR163","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/hmg\/ddv505","volume":"25","author":"R Bharadwaj","year":"2016","unstructured":"Bharadwaj, R., Cunningham, K. M., Zhang, K. & Lloyd, T. E. FIG4 regulates lysosome membrane homeostasis independent of phosphatase function. Hum. Mol. Genet. 25, 681\u2013692 (2016).","journal-title":"Hum. Mol. Genet."},{"key":"751_CR164","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/j.1460-9568.2011.07651.x","volume":"33","author":"I Katona","year":"2011","unstructured":"Katona, I. et al. Distinct pathogenic processes between Fig4-deficient motor and sensory neurons. Eur. J. Neurosci. 33, 1401\u20131410 (2011).","journal-title":"Eur. J. Neurosci."},{"key":"751_CR165","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1093\/brain\/awn114","volume":"131","author":"X Zhang","year":"2008","unstructured":"Zhang, X. et al. Mutation of FIG4 causes a rapidly progressive, asymmetric neuronal degeneration. Brain 131, 1990\u20132001 (2008).","journal-title":"Brain"},{"key":"751_CR166","doi-asserted-by":"publisher","first-page":"4868","DOI":"10.1093\/hmg\/ddp460","volume":"18","author":"CJ Ferguson","year":"2009","unstructured":"Ferguson, C. J., Lenk, G. M. & Meisler, M. H. Defective autophagy in neurons and astrocytes from mice deficient in PI(3,5)P2. Hum. Mol. Genet. 18, 4868\u20134878 (2009).","journal-title":"Hum. Mol. Genet."},{"key":"751_CR167","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.expneurol.2015.12.011","volume":"277","author":"A Kyotani","year":"2016","unstructured":"Kyotani, A. et al. Knockdown of the Drosophila FIG4 induces deficient locomotive behavior, shortening of motor neuron, axonal targeting aberration, reduction of life span and defects in eye development. Exp. Neurol. 277, 86\u201395 (2016).","journal-title":"Exp. Neurol."},{"key":"751_CR168","doi-asserted-by":"publisher","DOI":"10.1172\/JCI137159","volume":"131","author":"M Presa","year":"2021","unstructured":"Presa, M. et al. AAV9-mediated FIG4 delivery prolongs life span in Charcot-Marie-Tooth disease type 4J mouse model. J. Clin. Invest. 131, e137159 (2021).","journal-title":"J. Clin. Invest."},{"key":"751_CR169","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/sj.onc.1208223","volume":"24","author":"K Kishimoto","year":"2005","unstructured":"Kishimoto, K., Liu, S., Tsuji, T., Olson, K. A. & Hu, G. F. Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis. Oncogene 24, 445\u2013456 (2005).","journal-title":"Oncogene"},{"key":"751_CR170","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/abbs\/gmv131","volume":"48","author":"J Sheng","year":"2016","unstructured":"Sheng, J. & Xu, Z. Three decades of research on angiogenin: a review and perspective. Acta Biochim. Biophys. Sin. 48, 399\u2013410 (2016).","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"751_CR171","doi-asserted-by":"publisher","first-page":"861435","DOI":"10.1155\/2014\/861435","volume":"2014","author":"SH Lee","year":"2014","unstructured":"Lee, S. H., Kim, K. W., Min, K. M., Chang, S. I. & Kim, J. C. Angiogenin reduces immune inflammation via inhibition of TANK-binding kinase 1 expression in human corneal fibroblast cells. Mediat. Inflamm. 2014, 861435 (2014).","journal-title":"Mediat. Inflamm."},{"key":"751_CR172","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.febslet.2008.12.043","volume":"583","author":"H Fu","year":"2009","unstructured":"Fu, H. et al. Stress induces tRNA cleavage by angiogenin in mammalian cells. FEBS Lett. 583, 437\u2013442 (2009).","journal-title":"FEBS Lett."},{"key":"751_CR173","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1083\/jcb.200811106","volume":"185","author":"S Yamasaki","year":"2009","unstructured":"Yamasaki, S., Ivanov, P., Hu, G. F. & Anderson, P. Angiogenin cleaves tRNA and promotes stress-induced translational repression. J. Cell Biol. 185, 35\u201342 (2009).","journal-title":"J. Cell Biol."},{"key":"751_CR174","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/ana.21221","volume":"62","author":"D Wu","year":"2007","unstructured":"Wu, D. et al. Angiogenin loss-of-function mutations in amyotrophic lateral sclerosis. Ann. Neurol. 62, 609\u2013617 (2007).","journal-title":"Ann. Neurol."},{"key":"751_CR175","doi-asserted-by":"publisher","first-page":"11810","DOI":"10.1021\/bi701333h","volume":"46","author":"B Crabtree","year":"2007","unstructured":"Crabtree, B. et al. Characterization of human angiogenin variants implicated in amyotrophic lateral sclerosis. Biochemistry 46, 11810\u201311818 (2007).","journal-title":"Biochemistry"},{"key":"751_CR176","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2126","volume":"3","author":"N Thiyagarajan","year":"2012","unstructured":"Thiyagarajan, N., Ferguson, R., Subramanian, V. & Acharya, K. R. Structural and molecular insights into the mechanism of action of human angiogenin-ALS variants in neurons. Nat. Commun. 3, 1121 (2012).","journal-title":"Nat. Commun."},{"key":"751_CR177","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032479","volume":"7","author":"AK Padhi","year":"2012","unstructured":"Padhi, A. K., Kumar, H., Vasaikar, S. V., Jayaram, B. & Gomes, J. Mechanisms of loss of functions of human angiogenin variants implicated in amyotrophic lateral sclerosis. PLoS One 7, e32479 (2012).","journal-title":"PLoS One"},{"key":"751_CR178","doi-asserted-by":"publisher","DOI":"10.1038\/srep01225","volume":"3","author":"AK Padhi","year":"2013","unstructured":"Padhi, A. K., Jayaram, B. & Gomes, J. Prediction of functional loss of human angiogenin mutants associated with ALS by molecular dynamics simulations. Sci. Rep. 3, 1225 (2013).","journal-title":"Sci. Rep."},{"key":"751_CR179","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1093\/hmg\/ddm095","volume":"16","author":"V Subramanian","year":"2007","unstructured":"Subramanian, V. & Feng, Y. A new role for angiogenin in neurite growth and pathfinding: implications for amyotrophic lateral sclerosis. Hum. Mol. Genet. 16, 1445\u20131453 (2007).","journal-title":"Hum. Mol. Genet."},{"key":"751_CR180","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/hmg\/ddm290","volume":"17","author":"V Subramanian","year":"2008","unstructured":"Subramanian, V., Crabtree, B. & Acharya, K. R. Human angiogenin is a neuroprotective factor and amyotrophic lateral sclerosis associated angiogenin variants affect neurite extension\/pathfinding and survival of motor neurons. Hum. Mol. Genet. 17, 130\u2013149 (2008).","journal-title":"Hum. Mol. Genet."},{"key":"751_CR181","doi-asserted-by":"publisher","first-page":"14056","DOI":"10.1523\/JNEUROSCI.3399-08.2008","volume":"28","author":"D Kieran","year":"2008","unstructured":"Kieran, D. et al. Control of motoneuron survival by angiogenin. J. Neurosci. 28, 14056\u201314061 (2008).","journal-title":"J. Neurosci."},{"key":"751_CR182","doi-asserted-by":"publisher","first-page":"5024","DOI":"10.1523\/JNEUROSCI.6366-11.2012","volume":"32","author":"A Skorupa","year":"2012","unstructured":"Skorupa, A. et al. Motoneurons secrete angiogenin to induce RNA cleavage in astroglia. J. Neurosci. 32, 5024\u20135038 (2012).","journal-title":"J. Neurosci."},{"key":"751_CR183","doi-asserted-by":"publisher","first-page":"15095","DOI":"10.1074\/jbc.RA119.008491","volume":"294","author":"TT Hoang","year":"2019","unstructured":"Hoang, T. T., Johnson, D. A., Raines, R. T. & Johnson, J. A. Angiogenin activates the astrocytic Nrf2\/antioxidant-response element pathway and thereby protects murine neurons from oxidative stress. J. Biol. Chem. 294, 15095\u201315103 (2019).","journal-title":"J. Biol. Chem."},{"key":"751_CR184","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1517\/14728222.12.10.1229","volume":"12","author":"H Kishikawa","year":"2008","unstructured":"Kishikawa, H., Wu, D. & Hu, G. F. Targeting angiogenin in therapy of amyotrophic lateral sclerosis. Expert. Opin. Ther. Targets 12, 1229\u20131242 (2008).","journal-title":"Expert. Opin. Ther. Targets"},{"key":"751_CR185","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-60431-6","volume":"10","author":"KC Aluri","year":"2020","unstructured":"Aluri, K. C., Salisbury, J. P., Prehn, J. H. M. & Agar, J. N. Loss of angiogenin function is related to earlier ALS onset and a paradoxical increase in ALS duration. Sci. Rep. 10, 3715 (2020).","journal-title":"Sci. Rep."},{"key":"751_CR186","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2174\/1566523214666140302193709","volume":"14","author":"B Balakrishnan","year":"2014","unstructured":"Balakrishnan, B. & Jayandharan, G. R. Basic biology of adeno-associated virus (AAV) vectors used in gene therapy. Curr. Gene Ther. 14, 86\u2013100 (2014).","journal-title":"Curr. Gene Ther."},{"key":"751_CR187","doi-asserted-by":"publisher","first-page":"10220","DOI":"10.1073\/pnas.1001673107","volume":"107","author":"F Sonntag","year":"2010","unstructured":"Sonntag, F., Schmidt, K. & Kleinschmidt, J. A. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc. Natl Acad. Sci. USA 107, 10220\u201310225 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"751_CR188","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1128\/JVI.79.1.364-379.2005","volume":"79","author":"Z Yan","year":"2005","unstructured":"Yan, Z., Zak, R., Zhang, Y. & Engelhardt, J. F. Inverted terminal repeat sequences are important for intermolecular recombination and circularization of adeno-associated virus genomes. J. Virol. 79, 364\u2013379 (2005).","journal-title":"J. Virol."},{"key":"751_CR189","doi-asserted-by":"publisher","first-page":"10346","DOI":"10.1128\/JVI.00841-06","volume":"80","author":"VW Choi","year":"2006","unstructured":"Choi, V. W., McCarty, D. M. & Samulski, R. J. Host cell DNA repair pathways in adeno-associated viral genome processing. J. Virol. 80, 10346\u201310356 (2006).","journal-title":"J. Virol."},{"key":"751_CR190","doi-asserted-by":"publisher","first-page":"6920","DOI":"10.1523\/JNEUROSCI.22-16-06920.2002","volume":"22","author":"LJ Wang","year":"2002","unstructured":"Wang, L. J. et al. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J. Neurosci. 22, 6920\u20136928 (2002).","journal-title":"J. Neurosci."},{"key":"751_CR191","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s13311-021-01025-6","volume":"18","author":"G M\u00f2dol-Caballero","year":"2021","unstructured":"M\u00f2dol-Caballero, G. et al. Specific expression of glial-derived neurotrophic factor in muscles as gene therapy strategy for amyotrophic lateral sclerosis. Neurotherapeutics 18, 1113\u20131126 (2021).","journal-title":"Neurotherapeutics"},{"key":"751_CR192","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1038\/s41591-022-01956-3","volume":"28","author":"RH Baloh","year":"2022","unstructured":"Baloh, R. H. et al. Transplantation of human neural progenitor cells secreting GDNF into the spinal cord of patients with ALS: a phase 1\/2a trial. Nat. Med. 28, 1813\u20131822 (2022).","journal-title":"Nat. Med."},{"key":"751_CR193","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1126\/science.1086137","volume":"301","author":"BK Kaspar","year":"2003","unstructured":"Kaspar, B. K., Llad\u00f3, J., Sherkat, N., Rothstein, J. D. & Gage, F. H. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301, 839\u2013842 (2003).","journal-title":"Science"},{"key":"751_CR194","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1007\/s12035-016-0335-z","volume":"55","author":"H Lin","year":"2018","unstructured":"Lin, H. et al. Intramuscular delivery of scAAV9-hIGF1 prolongs survival in the hSOD1 G93A ALS mouse model via upregulation of D-amino acid oxidase. Mol. Neurobiol. 55, 682\u2013695 (2018).","journal-title":"Mol. Neurobiol."},{"key":"751_CR195","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.brainresbull.2018.02.015","volume":"139","author":"W Wang","year":"2018","unstructured":"Wang, W. et al. Systemic administration of scAAV9-IGF1 extends survival in SOD1G93A ALS mice via inhibiting p38 MAPK and the JNK-mediated apoptosis pathway. Brain Res. Bull. 139, 203\u2013210 (2018).","journal-title":"Brain Res. Bull."},{"key":"751_CR196","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/mus.27472","volume":"65","author":"ME Cudkowicz","year":"2022","unstructured":"Cudkowicz, M. E. et al. A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. Muscle Nerve 65, 291\u2013302 (2022).","journal-title":"Muscle Nerve"},{"key":"751_CR197","doi-asserted-by":"publisher","DOI":"10.1186\/2001-1326-3-21","volume":"3","author":"Y Gothelf","year":"2014","unstructured":"Gothelf, Y., Abramov, N., Harel, A. & Offen, D. Safety of repeated transplantations of neurotrophic factors-secreting human mesenchymal stromal stem cells. Clin. Transl. Med. 3, 21 (2014).","journal-title":"Clin. Transl. Med."},{"key":"751_CR198","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1001\/jamaneurol.2015.4321","volume":"73","author":"P Petrou","year":"2016","unstructured":"Petrou, P. et al. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1\/2 and 2a clinical trials. JAMA Neurol. 73, 337\u2013344 (2016).","journal-title":"JAMA Neurol."},{"key":"751_CR199","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1093\/brain\/awx370","volume":"141","author":"D Brenner","year":"2018","unstructured":"Brenner, D. et al. Hot-spot KIF5A mutations cause familial ALS. Brain 141, 688\u2013697 (2018).","journal-title":"Brain"},{"key":"751_CR200","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.neuron.2018.02.027","volume":"97","author":"A Nicolas","year":"2018","unstructured":"Nicolas, A. et al. Genome-wide analyses identify KIF5A as a novel ALS gene. Neuron 97, 1268\u20131283.e6 (2018).","journal-title":"Neuron"},{"key":"751_CR201","doi-asserted-by":"publisher","first-page":"14717","DOI":"10.1523\/JNEUROSCI.2770-14.2014","volume":"34","author":"PD Campbell","year":"2014","unstructured":"Campbell, P. D. et al. Unique function of kinesin Kif5A in localization of mitochondria in axons. J. Neurosci. 34, 14717\u201314732 (2014).","journal-title":"J. Neurosci."},{"key":"751_CR202","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/gtc.12936","volume":"27","author":"J Nakano","year":"2022","unstructured":"Nakano, J., Chiba, K. & Niwa, S. An ALS-associated KIF5A mutant forms oligomers and aggregates and induces neuronal toxicity. Genes. Cell 27, 421\u2013435 (2022).","journal-title":"Genes. Cell"},{"key":"751_CR203","doi-asserted-by":"publisher","first-page":"110598","DOI":"10.1016\/j.celrep.2022.110598","volume":"39","author":"DM Baron","year":"2022","unstructured":"Baron, D. M. et al. ALS-associated KIF5A mutations abolish autoinhibition resulting in a toxic gain of function. Cell Rep. 39, 110598 (2022).","journal-title":"Cell Rep."},{"key":"751_CR204","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202154234","volume":"23","author":"DC Pant","year":"2022","unstructured":"Pant, D. C. et al. ALS-linked KIF5A \u0394Exon27 mutant causes neuronal toxicity through gain-of-function. EMBO Rep. 23, e54234 (2022).","journal-title":"EMBO Rep."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-022-00751-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-022-00751-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-022-00751-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T14:13:01Z","timestamp":1672841581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-022-00751-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":204,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["751"],"URL":"https:\/\/doi.org\/10.1038\/s41582-022-00751-5","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,8]]},"assertion":[{"value":"10 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}